线粒体转移与移植的生物技术方法及治疗潜力

Biotechnological approaches and therapeutic potential of mitochondria transfer and transplantation.

作者信息

Kubat Gokhan Burcin, Picone Pasquale, Tuncay Erkan, Aryan Leila, Girgenti Antonella, Palumbo Laura, Turkel Ibrahim, Akat Firat, Singh Keshav K, Nuzzo Domenico

机构信息

Institute of Transplantation and Gene Sciences, Baskent University, Ankara, Türkiye.

Department of Exercise and Sport Sciences, Faculty of Health Sciences, Baskent University, Ankara, Türkiye.

出版信息

Nat Commun. 2025 Jul 1;16(1):5709. doi: 10.1038/s41467-025-61239-6.

DOI:10.1038/s41467-025-61239-6

PMID:40593725

Abstract

Mitochondrial dysfunction contributes to aging and diseases like neurodegeneration and cardiovascular disorders. Mitochondria transfer and transplantation (MTT) represent promising therapeutic strategies aimed at restoring cellular function by introducing functional mitochondria into damaged cells. However, challenges like transfer efficiency, stability, and cellular integration limit clinical application. Recent biotechnological advances-such as liposomes, extracellular vesicles, and surface modifications-enhance mitochondrial protection, targeting, and biocompatibility. This Perspective highlights recent progress in MTT, its therapeutic potential, and current limitations. We also discuss the need for scalable, clinically translatable approaches and appropriate regulatory frameworks to realize the full potential of mitochondria-based nanotherapies in modern medicine.

摘要

线粒体功能障碍会导致衰老以及神经退行性变和心血管疾病等病症。线粒体转移和移植（MTT）是一种很有前景的治疗策略，旨在通过将功能性线粒体引入受损细胞来恢复细胞功能。然而，诸如转移效率、稳定性和细胞整合等挑战限制了其临床应用。最近的生物技术进展，如脂质体、细胞外囊泡和表面修饰，增强了线粒体的保护、靶向性和生物相容性。本观点文章强调了MTT的最新进展、其治疗潜力和当前的局限性。我们还讨论了需要可扩展的、可临床转化的方法以及适当的监管框架，以在现代医学中充分发挥基于线粒体的纳米疗法的潜力。